Correction: Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials
- Andrew R. DiNardo1,2*corresponding author
- Wilbert Sabiiti3
- Stephen H. Gillespie3
- Sophia B. Georghiou4
- Norbert Heinrich5,6
- Norbert Hittel7
- Sami Taghlabi2
- Danna Carrero Longlax2
- Mikashmi Kohli4
- Ursula Panzner5,6
- Collins Musia8
- Christoph Lange2,8,9,10
- Anca Vasiliu2,8,9
- Rob J. W. Arts1
- Anna M. Mandalakas2,8,9
- Morten Ruhwald4
- Lieven J. Stuyver11
- Reinout van Crevel3,12
- 1Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands
- 2The Global Tuberculosis Program, Texas Children’s Hospital, Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States
- 3Division of Infectious Disease and Global Health, University of St Andrews, St Andrews, United Kingdom
- 4FIND, Geneva, Switzerland
- 5Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany
- 6German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
- 7Otsuka Novel Products GmbH, Munich, Germany
- 8German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany
- 9Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
- 10Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany
- 11Janssen Global Public Health R&D, Janssen Pharmaceutica NV, Beerse, Belgium
- 12Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
Abstract
Keywords
An incorrect Funding statement was provided. The correct Funding statement reads:
“This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research”.
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Footnotes
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
Citation
DiNardo, A. R., et al. (2026). Correction: Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials. Frontiers in Antibiotics, Volume 4. https://doi.org/
- Received
- Accepted
- Published
- Volume
- 4 - 2026
Copyright
Copyright © 2026 DiNardo, Sabiiti, Gillespie, Georghiou, Heinrich, Hittel, Taghlabi, Longlax, Kohli, Panzner, Musia, Lange, Vasiliu, Arts, Mandalakas, Ruhwald, Stuyver and van Crevel.
License: https://creativecommons.org/licenses/by/4.0/
*Correspondence: Andrew R. DiNardo
Article metrics
- Views
- 0
- Downloads
- 0
- Citations
- 0
- Shares
- 0